The purpose of this study is to see if an anti-HIV medication known as Stribild
(elvitegravir/cobicistat/emtricitabine/tenofovir DF) is safe, tolerable and acceptable when
taken for 28 days, once a day after a possible, sexual, exposure to the Human Immune
Deficiency Virus (HIV).
Phase:
Phase 4
Details
Lead Sponsor:
Kenneth H. Mayer, MD
Collaborator:
Gilead Sciences
Treatments:
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine Tenofovir